HECTD2 and neoplasm: Given that the response to PD-1 blockade was not strongly associated with tumour mutation load and, by extension, expected tumour neoantigenicity in either of these cohorts [35, 36], the link between elevated HECTD2 expression and lack of immunotherapy response suggest that HECTD2 activity may counteract T cell anti-tumour immunity.